miR‑148a‑3p suppresses epithelial ovarian cancer progression primarily by targeting c‑Met

Wang,Wen; Dong,Jing; Wang,Maoxiu; Yao,Shujuan; Tian,Xiangyu; Cui,Xiujuan; Fu,Shijie; Zhang,Shiqian

doi:10.3892/ol.2018.8110

miR‑148a‑3p suppresses epithelial ovarian cancer progression primarily by targeting c‑Met

Authors:
- Wen Wang
- Jing Dong
- Maoxiu Wang
- Shujuan Yao
- Xiangyu Tian
- Xiujuan Cui
- Shijie Fu
- Shiqian Zhang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology Jining Medical University Affiliated Tengzhou Central People's Hospital, Tengzhou, Shandong 277599, P.R. China, Department of Medical Imaging, Jining Medical University Affiliated Tengzhou Central People's Hospital, Tengzhou, Shandong 277599, P.R. China, Department of Clinical Medicine, Anhui Medical University, Hefei, Anhui 230032, P.R. China, Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: February 23, 2018 https://doi.org/10.3892/ol.2018.8110
Pages: 6131-6136
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) are a group of small non‑coding RNAs that modulate post‑transcriptional gene expression. It has been demonstrated that various miRNAs may be expressed at different levels in different types of tumors. The present study assessed the role of microRNA‑148a‑3p (miR‑148a‑3p) in epithelial ovarian cancer (EOC). The results demonstrated that miR‑148a‑3p was decreased in EOC tissues and that a lower miRa‑148‑3p concentration was associated with a higher overall survival rate. Transfection of miR‑148a‑3p suppressed the invasive and proliferative capacity of SKOV3 cells. The induced overexpression of miR‑148a‑3p significantly inhibited the relative luciferase activity of the pmirGLO‑c‑Met‑3'untranslated region compared with an empty vector. In addition, c‑Met silencing led to a decrease in the invasive and proliferative capacity of EOC cells. The inhibition of miR‑148a‑3p did not increase the invasiveness of SKOV3 cells, even when c‑Met was silenced. To the best of our knowledge, the present study is the first to demonstrate that miR‑148a‑3p expression is decreased in EOC cancer tissues and cell lines. The present study therefore demonstrated that miR‑148a‑3p may serve as a tumor suppressor in EOC by targeting c‑Met.

View Figures

View References

1	McGuire V, Jesser CA and Whittemore AS: Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol. 84:399–403. 2002. View Article : Google Scholar : PubMed/NCBI
2	Li H, Zhang H, Zhao S, Shi Y, Yao J, Zhang Y, Guo H and Liu X: Overexpression of MACC1 and the association with hepatocyte growth factor/c-Met in epithelial ovarian cancer. Oncol Lett. 9:1989–1996. 2015. View Article : Google Scholar : PubMed/NCBI
3	Gislefoss RE, Langseth H, Bolstad N, Nustad K and Morkrid L: HE4 as an early detection biomarker of epithelial ovarian cancer: Investigations in prediagnostic specimens from the janus serumbank. Int J Gynecol Cancer. 25:1608–1615. 2015. View Article : Google Scholar : PubMed/NCBI
4	Lawrenson K, Grun B, Lee N, Mhawech-Fauceglia P, Kan J, Swenson S, Lin YG, Pejovic T, Millstein J and Gayther SA: NPPB is a novel candidate biomarker expressed by cancer-associated fibroblasts in epithelial ovarian cancer. Int J Cancer. 136:1390–1401. 2015. View Article : Google Scholar : PubMed/NCBI
5	Masoumi-Moghaddam S, Amini A, Wei AQ, Robertson G and Morris DL: Sprouty 2 protein, but not Sprouty 4, is an independent prognostic biomarker for human epithelial ovarian cancer. Int J Cancer. 137:560–570. 2015. View Article : Google Scholar : PubMed/NCBI
6	Stiekema A, Boldingh QJ, Korse CM, van der Noort V, Boot H, van Driel WJ, Kenter GG and Lok CA: Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin. Gynecol Oncol. 136:562–566. 2015. View Article : Google Scholar : PubMed/NCBI
7	Wu J, Yin H, Zhu J, Buckanovich RJ, Thorpe JD, Dai J, Urban N and Lubman DM: Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study. PLoS One. 10:e01211122015. View Article : Google Scholar : PubMed/NCBI
8	Wang L, Mezencev R, Svajdler M, Benigno BB and McDonald JF: Ectopic over-expression of miR-429 induces mesenchymal-to-epithelial transition (MET) and increased drug sensitivity in metastasizing ovarian cancer cells. Gynecol Oncol. 134:96–103. 2014. View Article : Google Scholar : PubMed/NCBI
9	Ayhan A, Ertunc D, Tok EC and Ayhan A: Expression of the c-Met in advanced epithelial ovarian cancer and its prognostic significance. Int J Gynecol Cancer. 15:618–623. 2005. View Article : Google Scholar : PubMed/NCBI
10	Zhang RT, Shi HR, Huang HL, Chen ZM, Liu HN and Yuan ZF: Expressions of MACC1, HGF, and C-met protein in epithelial ovarian cancer and their significance. Nan Fang Yi Ke Da Xue Xue Bao. 31:1551–1555. 2011.(In Chinese). PubMed/NCBI
11	Chen J, Wang L, Matyunina LV, Hill CG and McDonald JF: Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Gynecol Oncol. 121:200–205. 2011. View Article : Google Scholar : PubMed/NCBI
12	Liu J, Wu X, Liu H, Liang Y, Gao X, Cai Z, Wang W and Zhang H: Expression of microRNA-30a-5p in drug-resistant and drug-sensitive ovarian cancer cell lines. Oncol Lett. 12:2065–2070. 2016. View Article : Google Scholar : PubMed/NCBI
13	Dong P, Xiong Y, Watari H, Hanley SJ, Konno Y, Ihira K, Yamada T, Kudo M, Yue J and Sakuragi N: miR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells. J Exp Clin Cancer Res. 35:1322016. View Article : Google Scholar : PubMed/NCBI
14	Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray HJ, Hakam A, et al: Ovarian cancer, version 2.2013. J Natl Compr Canc Netw. 11:1199–1209. 2013. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Wei Z, Liu Y, Wang Y, Zhang Y, Luo Q, Man X, Wei F and Yu X: Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell proliferation, invasion, and drug resistance of ovarian cancer. Med Oncol. 33:1262016. View Article : Google Scholar : PubMed/NCBI
17	Kanlikilicer P, Saber M, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Filant J, Silva AM, Rodriguez-Aguayo C, et al: Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells. Cancer Res. 76:7194–7207. 2016. View Article : Google Scholar : PubMed/NCBI
18	Azizmohammadi S, Azizmohammadi S, Safari A, Kosari N, Kaghazian M, Yahaghi E and Seifoleslami M: The role and expression of miR-100 and miR-203 profile as prognostic markers in epithelial ovarian cancer. Am J Transl Res. 8:2403–2410. 2016.PubMed/NCBI
19	Li L, Xu QH, Dong YH, Li GX, Yang L, Wang LW and Li HY: miR-181a upregulation is associated with epithelial-to-mesenchymal transition (EMT) and multidrug resistance (MDR) of ovarian cancer cells. Eur Rev Med Pharmacol Sci. 20:2004–2010. 2016.PubMed/NCBI
20	Meng X, Muller V, Milde-Langosch K, Trillsch F, Pantel K and Schwarzenbach H: Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget. 7:16923–16935. 2016. View Article : Google Scholar : PubMed/NCBI
21	Sulaiman SA, Ab Mutalib NS and Jamal R: miR-200c regulation of metastases in ovarian cancer: Potential role in epithelial and mesenchymal transition. Front Pharmacol. 7:2712016. View Article : Google Scholar : PubMed/NCBI
22	Xia B, Li H, Yang S, Liu T and Lou G: miR-381 inhibits epithelial ovarian cancer malignancy via YY1 suppression. Tumour Biol. 37:9157–9167. 2016. View Article : Google Scholar : PubMed/NCBI
23	Yan W, Chen J, Chen Z and Chen H: Deregulated miR-296/S100A4 axis promotes tumor invasion by inducing epithelial-mesenchymal transition in human ovarian cancer. Am J Cancer Res. 6:260–269. 2016.PubMed/NCBI
24	Wu X, Zhou J, Rogers AM, Jänne PA, Benedettini E, Loda M and Hodi FS: c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential. Melanoma Res. 22:123–132. 2012. View Article : Google Scholar : PubMed/NCBI
25	de Melo Gagliato D, Jardim DL, Falchook G, Tang C, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, et al: Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. Clin Breast Cancer. 14:468–474. 2014. View Article : Google Scholar : PubMed/NCBI
26	Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, et al: MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 5:1837–1845. 2014. View Article : Google Scholar : PubMed/NCBI
27	Chiyomaru T, Seki N, Inoguchi S, Ishihara T, Mataki H, Matsushita R, Goto Y, Nishikawa R, Tatarano S, Itesako T, et al: Dual regulation of receptor tyrosine kinase genes EGFR and c-Met by the tumor-suppressive microRNA-23b/27b cluster in bladder cancer. Int J Oncol. 46:487–496. 2015. View Article : Google Scholar : PubMed/NCBI
28	Gardner FP, Serie DJ, Salomao DR, Wu KJ, Markovic SN, Pulido JS and Joseph RW: c-MET expression in primary and liver metastases in uveal melanoma. Melanoma Res. 24:617–620. 2014. View Article : Google Scholar : PubMed/NCBI